All articles by Ranjith Dharma
Ranjith Dharma
Amgen receives FDA approval for Kyprolis combination therapy to treat multiple myeloma
The US Food and Drug Administration (FDA) has granted approval for Amgens’ Kyprolis (carfilzomib) combination therapy to treat patients with relapsed or refractory multiple myeloma.
Pharma companies urge governments to take collective action on drug-resistant infections
Around 85 international pharmaceutical, generics, diagnostics and biotechnology firms have urged governments and industry to take comprehensive action on drug-resistant infections called superbugs.
Upsher-Smith and Saniona to develop new therapeutics for neurological disorders
Upsher-Smith Laboratories wholly-owned subsidiary Proximagen has partnered with biotech firm Saniona to develop novel therapeutics for neurological disorders.
AbbVie’s venetoclax-rituximab combination gets FDA breakthrough therapy status to treat R/R CLL
Biopharmaceutical firm AbbVie has received breakthrough therapy status from the US Food and Drug Administration (FDA) for its venetoclax in combination with rituximab to treat patients with relapsed / refractory chronic lymphocytic leukemia (R/R CLL).
Acorda to acquire Finland’s biopharmaceutical firm Biotie for $363m
Acorda Therapeutics has signed an agreement to acquire Finland-based biopharmaceutical firm Biotie Therapies for approximately $363m.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
MediciNova’s ibudilast gets FDA rare paediatric disease status to treat Krabbe disease
MediciNova has received rare paediatric disease status from the US Food and Drug Administration (FDA) for its MN-166 (ibudilast) to treat Type 1 Early Infantile Krabbe disease.
Wellstat’s Vistogard receives FDA approval to treat chemotherapy overdose patients
Wellstat Therrpeutics has received approval from the US Food and Drug Administration (FDA) for its Vistogard (uridine triacetate) to treat adult and paediatric patients following an overdose of the chemotherapy agents 5-Fluorouracil (5-FU) or capecitabine.
Court rules UK firm Reckitt Benckiser’s Nurofen made misleading pain relief claims
The Federal Court of Australia has ruled that UK-based Reckitt Benckiser’s Nurofen made misleading pain relief claims.
Omnio and ProMetic partner to develop new drug for chronic wounds
Switzerland-based biotech firm Omnio has teamed-up with Canadian pharmaceutical firm ProMetic to develop a new drug for slow-healing chronic wounds.
Baxalta receives European approval for Obizur to treat haemophilia A
Baxalta has received marketing approval from the European Commission for its Obizur (Antihaemophilic Factor [ecombinant], Porcine Sequence) to treat adult patients with haemophilia A.